Non-Alcoholic Fatty Liver Disease May Be a Risk Factor for Liver Metastasis After Radical Surgery for Colorectal Cancer: A Retrospective Study
Journal of Gastrointestinal Cancer · 2024
DOI: 10.1007/s12029-024-01042-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal Cancer, 2024. Verfasst von Takashi Miyata und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and Digestive Surgery, Kanazawa Medical University Hospital, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa, 920-0293, Japan. ryutami5…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Non-alcoholic Fatty Liver Disease, Liver Neoplasms, Hepatectomy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Distant metastasis develops in approximately one-third of patients with colorectal cancer (CRC) who undergo radical surgery, and colorectal liver metastasis (CRLM) is the most common form of distant metastasis in CRC. Hepatectomy is the only potentially curative treatment for CRLM, but few patients with metastatic CRC meet the criteria for this radical resection, and the 5-year survival rate is poor. Identifying risk factors for CRLM is critical. Non-alcoholic fatty liver disease (NAFLD) is an independent risk factor for CRC. However, the effect of NAFLD on CRC liver metastasis after radical surgery remains unclear. Therefore, we examined the impact of NAFLD-associated hepatic fibrosis on liver metastasis after radical surgery for CRC. METHODS: We retrospectively analyzed data from 388 patients who underwent curative surgery for CRC at our hospital between April 2008 and March 2015. The patients' clinical results, surgical procedures, postoperative course, and pathological and survival data were collected from the hospital records. The NAFLD fibrosis score was calculated and used to divide the patients into two groups (NAFLD and non-NAFLD). RESULTS: Recurrence was observed in 83/388 (21.4%) patients after a mean follow-up of 65.6 ± 15.1 months. Twenty-five patients had liver metastasis: 8 in the NAFLD group (8/45; 17.8%) and 17 in the non-NALFD group (17/343; 5.0%) (p = 0.004). Liver metastasis-free survival was significantly worse in the NAFLD than non-NAFLD group (p < 0.001). NAFLD and cancer stage were independent risk factors for liver metastasis recurrence. CONCLUSION: NAFLD may be a risk factor for liver metastasis in patients with CRC who undergo curative surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General and Digestive Surgery, Kanazawa Medical University Hospital, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa, 920-0293, Japan. ryutami5383917@gmail.com.
- Department of General and Digestive Surgery, Kanazawa Medical University Hospital, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa, 920-0293, Japan.
Zitieren
APA
Miyata, T., Shinden, Y., Motoyama, S., Sannomiya, Y., Tamezawa, H., Nagayama, T., Nishiki, H., Hashimoto, A., Kaida, D., Fujita, H., Ueda, N., & Takamura, H. (2024). Non-Alcoholic Fatty Liver Disease May Be a Risk Factor for Liver Metastasis After Radical Surgery for Colorectal Cancer: A Retrospective Study. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-024-01042-6
Vancouver
Miyata T, Shinden Y, Motoyama S, Sannomiya Y, Tamezawa H, Nagayama T, et al. Non-Alcoholic Fatty Liver Disease May Be a Risk Factor for Liver Metastasis After Radical Surgery for Colorectal Cancer: A Retrospective Study. Journal of Gastrointestinal Cancer. 2024. doi:10.1007/s12029-024-01042-6
BibTeX
@article{Miyata2024,
author = {Miyata, Takashi and Shinden, Yuki and Motoyama, Shota and Sannomiya, Yuta and Tamezawa, Hozumi and Nagayama, Taigo and Nishiki, Hisashi and Hashimoto, Akifumi and Kaida, Daisuke and Fujita, Hideto and Ueda, Nobuhiko and Takamura, Hiroyuki},
title = {Non-Alcoholic Fatty Liver Disease May Be a Risk Factor for Liver Metastasis After Radical Surgery for Colorectal Cancer: A Retrospective Study},
journal = {Journal of Gastrointestinal Cancer},
year = {2024},
doi = {10.1007/s12029-024-01042-6}
}
EUVIMED